Bicara Therapeutics (Nasdaq: BCAX) granted inducement equity awards to four new employees under its 2026 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
The grants cover 191,425 stock options at an exercise price of $28.91 per share, with time-based vesting tied to continued service.
New inducement options for 191,425 shares at $28.91 add to equity-based compensation outside stockho...
Analysis
New inducement options for 191,425 shares at $28.91 add to equity-based compensation outside stockholder-approved plans, against a backdrop of active shelf capacity and elevated short interest; investors may watch for further grants or offerings that change dilution expectations.
Key Figures
Inducement option shares:191,425 sharesExercise price:$28.91 per sharePar value:$0.0001 per share+5 more
8 metrics
Inducement option shares191,425 sharesAggregate non-qualified stock options granted to four new employees
Exercise price$28.91 per shareEquals Nasdaq closing price on July 1, 2026
Par value$0.0001 per sharePar value of Bicara common stock underlying options
Employees receiving grants4 employeesNew hires granted options under 2026 Inducement Plan
Initial vesting portionOne-fourth of sharesVests on first anniversary of each employee’s start date
Remaining vesting schedule12 quarterly installmentsBalance vests in 12 equal quarterly installments after first anniversary
Grant dateJuly 1, 2026Date options were granted under 2026 Inducement Plan
Plan adoption dateJanuary 2026Bicara’s board adopted the 2026 Inducement Plan
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent BCAX headlines have more often seen positive price reactions, with the prior inducement grant notably drawing a negative move.
Key Terms
non-qualified stock options, par value, nasdaq listing rule 5635(c)(4), equity incentive plans, +1 more
5 terms
non-qualified stock optionsfinancial
"non-qualified stock options to purchase 191,425 shares of Bicara’s common stock"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
par valuefinancial
"common stock, par value $0.0001 per share, with an exercise price"
Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.
nasdaq listing rule 5635(c)(4)regulatory
"as a material inducement to the employees entering into employment with Bicara in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
equity incentive plansfinancial
"awards were granted outside of Bicara’s stockholder-approved equity incentive plans"
Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.
inducement planfinancial
"four new employees under Bicara’s 2026 Inducement Plan as a material inducement"
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on July 1, 2026 to four new employees under Bicara’s 2026 Inducement Plan as a material inducement to employment.
The employees received, in the aggregate, non-qualified stock options to purchase 191,425 shares of Bicara’s common stock, par value $0.0001 per share, with an exercise price of $28.91 per share, equal to the closing price of Bicara’s common stock as reported by Nasdaq on July 1, 2026.One-fourth of the shares vest on the first anniversary of the employee’s applicable start date, with the remaining shares vesting in 12 equal quarterly installments thereafter, subject to the employee’s continued service with the company through each applicable vesting date.
The above-described awards were granted outside of Bicara’s stockholder-approved equity incentive plans and are pursuant to Bicara’s 2026 Inducement Plan, which was adopted by Bicara’s board of directors in January 2026.The awards were approved by the compensation committee of Bicara’s board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with Bicara in accordance with Nasdaq Listing Rule 5635(c)(4).
About Bicara Therapeutics Bicara is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara has built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This approach was deployed in the development of Bicara’s lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to a human transforming growth factor beta (TGF-β) ligand trap. By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment (TME). Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, which Bicara believes will lead to deep and durable responses and an increase in overall survival, while reducing the potentialadverse effects previouslyassociated with systemic TGF-β inhibition. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.
Contacts
Investors: Rachel Frank IR@bicara.com
Media: Tim Palmer tim.palmer@bicara.com
FAQ
What inducement stock option grants did Bicara Therapeutics (BCAX) announce on July 2, 2026?
Bicara Therapeutics announced non-qualified stock options for 191,425 shares granted to four new employees. According to Bicara, these options were issued under the 2026 Inducement Plan as a material inducement to employment, outside stockholder-approved equity incentive plans.
What is the exercise price of the new Bicara Therapeutics (BCAX) inducement options?
The exercise price of the inducement options is $28.91 per share. According to Bicara, this price equals the closing price of Bicara common stock on Nasdaq on July 1, 2026, the grant date for these awards.
How do the Bicara Therapeutics (BCAX) inducement grants vest for new employees?
The inducement options vest over time based on continued service. According to Bicara, one-fourth of each grant vests on the first anniversary of the employee’s start date, with the remainder vesting in 12 equal quarterly installments thereafter.
Under which plan were the July 2026 Bicara Therapeutics (BCAX) inducement options granted?
The options were granted under Bicara’s 2026 Inducement Plan. According to Bicara, this plan was adopted by the board in January 2026 and is separate from stockholder-approved equity incentive plans, aligning with Nasdaq Listing Rule 5635(c)(4).
Who approved the July 2026 Bicara Therapeutics (BCAX) inducement option awards?
The compensation committee of Bicara’s board of directors approved the awards. According to Bicara, this committee is composed solely of independent directors and approved the grants as a material inducement for the employees to enter employment.
How does Nasdaq Listing Rule 5635(c)(4) relate to Bicara Therapeutics (BCAX) inducement grants?
Nasdaq Listing Rule 5635(c)(4) permits inducement grants outside stockholder-approved plans in specific circumstances. According to Bicara, the July 1, 2026 option awards qualify as material inducements to employment under this rule and were structured accordingly.
